The Industry’s First and Only FDA-Inspected Direct-to-Patient Site
Our contribution to overall study enrollment is consistently among the highest across all participating sites. By expanding access beyond the typical 30-mile catchment area of traditional brick-and-mortar sites, we routinely deliver top-tier enrollment velocity.
Science 37 eliminates participation barriers by delivering clinical trials directly to patients' homes.
Explore how we can scale patient accessibility and streamline enrollment for your specific protocol.
Investigators licensed across all 50 states provide clinical trial access to 100% of the U.S. target population, driving seamless, diverse enrollment.
Streamlined Start-Up: One 1572, One Budget, and Central IRB Approvals
Study start-up times accelerated through comprehensive operational support.
Direct-to-Patient IMP Management
Investigational Medicinal Product (IMP) is shipped directly to the patient’s home 1–2 days before dosing with oversight from our Research-Grade Nurses maintaining a strict chain of custody, administration of IMP, and standardized temperature monitoring.
Centralized Kit Deployment
Logistical support provides management and oversight of clinical equipment and lab kits centrally, shipping them from our NC headquarters 1–2 weeks before a visit. Upon arrival, our Research-Grade Nurses verify delivery and prepare setup.
Specialized Research-Grade Nurses
An in-house network of 150+ multi-state licensed Research-Grade Nurse employees complete rigorous protocol-specific training, GCP/IATA certifications, and an Investigator-led clinical competency exam before conducting any visits.
Rigorous Investigator Oversight
Patient safety and data integrity remain our top priorities. Science 37 Investigators maintain strict oversight of visits via telemedicine, ensuring direct visualization of both the nurse and the participant. This enables real-time guidance of clinical assessments, immediate electronic data capture (eSource) review, and proactive adverse event management, mirroring or exceeding the rigor of a traditional site in a direct-to-patient model.
